Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor
- 1 August 2017
- journal article
- Published by Elsevier in Vascular Pharmacology
- Vol. 93-95, 42-47
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantationVascular Pharmacology, 2016
- Platelet‐reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2014
- Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive ManagementJournal of Cardiovascular Pharmacology, 2014
- 1,25(OH) 2 vitamin D 3 ‐dependent inhibition of platelet Ca 2+ signaling and thrombus formation in klotho‐deficient miceThe FASEB Journal, 2014
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and BleedingJACC, 2013
- Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyThe Lancet, 2013
- Early glycoprotein IIb‐IIIa inhibitors in primary angioplasty‐abciximab long‐term results (EGYPT‐ALT) cooperation: individual patient’s data meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Low‐molecular‐weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST‐elevation myocardial infarction: a meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Variability in Individual Responsiveness to ClopidogrelJACC, 2007
- Resistance to clopidogrel: A review of the evidenceJACC, 2005